Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BMRA vs BWAY: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BWAY Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 7–3 Matrix Metrics)

BWAY Overall Winner 6-Pillar Tally: BMRA 0 – 5 BWAY (1 Tie) Matrix Metrics: BMRA 3 – 7 BWAY

As of Nov 16, 2026, Brainsway Ltd. (BWAY) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BMRA carries a Unified Composite Score of 44.5/100 (HOLD) at $1.36 (N/M Forward P/E, -125.2% operating margin), whereas BWAY carries 33.8/100 (SELL) at $9.34 (17.9x Forward P/E, 12.5% operating margin).

  • Composite vs. Pillar Nuance: While BMRA currently prints a higher short-term Unified Composite Score (44.5/100 HOLD vs. BWAY 33.8/100 SELL), BWAY captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (12.5% vs. -125.2% operating margin) and revenue trajectory (+35.4% vs. -8.3% YoY).
  • Technical & Structure Timing Caution: BMRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0); meanwhile BWAY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BMRA vs BWAY
BMRA NASDAQ
Biomerica Inc
In Vitro & In Vivo Diagnostic Substances
$1.36
+0.0% 1D
Market Cap $6.0M
TTM Revenue $4.3M
Forward P/E N/M
Beta / 30D Vol 0.67β · 62% Vol
Unified Composite Score
44.5 / 100 HOLD
Tech 40.0 Fund 47.0 Flow 50.0 Mom 44.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.7%), weak momentum, RSI 28
RSI-14: 28.0 · SMA20: $1.62 · SMA50: $1.96
BWAY NASDAQ Head-to-Head Winner
Brainsway Ltd. American Depositary Shares
Surgical & Medical Instruments & Apparatus
$9.34
-7.62% 1D
Market Cap $412.6M
TTM Revenue $108M
Forward P/E 17.9x
Beta / 30D Vol 1.86β · 67% Vol
Unified Composite Score
33.8 / 100 SELL
Tech 34.0 Fund 45.0 Flow 50.0 Mom 49.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.0%), weak momentum, RSI 33
RSI-14: 32.7 · SMA20: $11.13 · SMA50: $12.16

6-Pillar Scorecard Institutional Category Breakdown (BMRA 0 – 5 BWAY)

Columns: Metric · BMRA · BWAY
1. Valuation Multiples BWAY
Forward P/E N/M 17.9x
Trailing P/E N/M 42.7x
PEG Ratio N/M N/M
EV / Revenue 1.1x 3.8x
2. Growth & Scale BWAY
Revenue Growth (YoY) -8.3% +35.4%
Earnings Growth (YoY) +0.0% +59.8%
TTM Revenue (USD) $4.3M $108M
Market Cap $6.0M $412.6M
3. Profitability & Quality BWAY
Gross Margin 0.9% 75.3%
Operating Margin -125.2% 12.5%
Net Profit Margin -115.5% 15.6%
Return on Equity (ROE) -113.8% 12.8%
4. Balance Sheet & Cash Flow BWAY
Cash Generation (TTM) -$3.2M $15M EBITDA
Cash Flow Margin -73.5% 14.0% EBITDA Mgn
Net Cash / Leverage $1.1M Net Cash $1.97 Book/Sh · 12.8% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 111.0% (77th %ile)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat BWAY
OpEx & R&D Intensity N/A 62.8% of Rev ($68M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BMRA (3) vs BWAY (7)
Institutional Metric BMRA BWAY Criterion Row Edge
Market Capitalization
Scale
$6.0M $412.6M Larger Scale BWAY
Trailing P/E Ratio
Valuation
N/M 42.7x Lower Multiple BWAY
Forward P/E Ratio
Valuation
N/M 17.9x Lower Multiple BWAY
Revenue Growth (YoY)
Growth
-8.3% +35.4% Higher Growth BWAY
Operating Margin (TTM)
Profitability
-125.2% 12.5% Higher Margin BWAY
Net Profit Margin
Profitability
-115.5% 15.6% Higher Margin BWAY
Return on Equity (ROE)
Capital Efficiency
-113.8% 12.8% Higher ROE BWAY
52-Week Range Position
Momentum
5% ($1–$3) 0% ($9–$27) Stronger Trend BMRA
Beta / 30D Volatility
Risk Regime
0.67β · 62% Vol 1.86β · 67% Vol Lower Realized Risk BMRA
Unified Institutional Score
Composite Signal
44.5 / 100 (HOLD) 33.8 / 100 (SELL) Higher Composite BMRA
Trailing 12M Revenue (USD)
Operating Scale
$4.3M $108M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
0.9% 75.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.1x EV/Rev N/M PEG · 3.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$3.2M ($1.1M Net Cash) $15M EBITDA ($1.97 Book/Sh · 12.8% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BWAY +8.13 pp
BMRA: -26.49% · BWAY: -18.36%
3M Horizon BMRA +21.29 pp
BMRA: -15.0% · BWAY: -36.29%
6M Horizon BWAY +2.33 pp
BMRA: -39.56% · BWAY: -37.23%
1Y Horizon BWAY +3.94 pp
BMRA: -45.6% · BWAY: -41.66%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BMRA vs BWAY. Trailing 12-month operating profitability (BMRA -125.2% vs BWAY 12.5%) and valuation multiples (BMRA N/M vs BWAY 17.9x Forward P/E) are benchmarked directly in Pillar 4 below.

BMRA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.3M
Gross Margin0.9%
Op. Margin-125.2%
ROE / Fwd P/E-113.8% · N/M
BWAY ADR TTM Benchmark FX-Normalized USD
TTM Revenue$108M
Gross Margin75.3%
Op. Margin12.5%
ROE / Fwd P/E12.8% · 17.9x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BMRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BMRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BWAY UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 111.0%
IV Percentile 77th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BWAY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BMRA Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $6.0M market capitalization and -125.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BWAY Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $412.6M market capitalization and 12.5% operating margin.
OpEx & R&D Reinvestment 62.8% of Rev ($68M)
90D Engineering Disclosures 0 Published

Investor FAQ BMRA vs BWAY Key Questions & Quantitative Answers

As of Nov 16, 2026, Brainsway Ltd. (BWAY) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BMRA carries a Unified Composite Score of 44.5/100 (HOLD) at $1.36 (N/M Forward P/E, -125.2% operating margin), whereas BWAY carries 33.8/100 (SELL) at $9.34 (17.9x Forward P/E, 12.5% operating margin). Composite vs. Pillar Nuance: While BMRA currently prints a higher short-term Unified Composite Score (44.5/100 HOLD vs. BWAY 33.8/100 SELL), BWAY captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (12.5% vs. -125.2% operating margin) and revenue trajectory (+35.4% vs. -8.3% YoY). Technical & Structure Timing Caution: BMRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0); meanwhile BWAY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BWAY leads the Growth & Scale pillar: BMRA posts -8.3% YoY revenue growth and +0.0% YoY earnings growth on $4.3M TTM revenue (0.9% gross margin, -125.2% operating margin), compared with BWAY at +35.4% YoY revenue growth and +59.8% YoY earnings growth on $108M TTM revenue (75.3% gross margin, 12.5% operating margin). On trailing 12-month operating scale, BMRA generates $4.3M in USD-normalized revenue versus $108M for BWAY. In operating R&D and SG&A reinvestment, BMRA deploys N/A (0 90-day corporate R&D disclosures) versus 62.8% of Rev ($68M) (0 disclosures) for BWAY.

BWAY screens cheaper on headline valuation multiples. BMRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-73.5% FCF margin), whereas BWAY trades at 17.9x Forward P/E, 42.7x Trailing P/E, N/M PEG, and 3.8x EV/Revenue (14.0% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BMRA (-113.8% ROE) versus BWAY (12.8% ROE) capital efficiency.

In options market volatility and institutional positioning, BMRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.67β · 62% Vol realized risk). By comparison, BWAY carries 111.0% implied volatility (77th %ile, Elevated (60th–80th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.86β · 67% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.